January 14, 2022
1 min read

FDA approves Ryaltris nasal spray for seasonal allergic rhinitis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA approved olopatadine hydrochloride and mometasone furoate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis in adults and children aged 12 years and older, according to a press release.

Olopatadine hydrochloride and mometasone furoate (Ryaltris, Glenmark Pharmaceuticals) is a metered, fixed-dose, aqueous suspension, prescription drug product nasal spray. It contains 665 µg olopatadine hydrochloride, a histamine-1 receptor inhibitor, and 25 µg mometasone furoate, a corticosteroid.

FDA headquarters
Source: Adobe Stock

“The FDA’s approval of Ryaltris represents a major milestone for Glenmark and clearly supports our efforts to bring innovative treatment options in our key therapeutic areas,” Robert Crockart, chief commercial officer of Glenmark Pharmaceuticals, said in the press release. “With this [new drug application] approval, we look forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms.”

The recommended daily dose of the nasal spray is two sprays in each nostril twice daily.